Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Merck Kgaa ADR (OP: MKKGY ) 34.98 +1.52 (+4.54%) Streaming Delayed Price Updated: 3:59 PM EDT, Jul 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Merck Kgaa ADR Pfizer Clears Required Regulatory Hurdles To Complete $43B Seagen Acquisition December 12, 2023 Pfizer Inc (NYSE: PFE) Via Benzinga Merck Germany's Two Pivotal Trials Flunk In Multiple Sclerosis December 06, 2023 Merck KGaA (OTC: MKGAF) (OTC: Via Benzinga Life Sciences Player Repligen's Strategic European Acquisition - What It Means for Investors September 26, 2023 Repligen Corporation (NASDAQ: RGEN) agreed to acquire Sweden-based privately-held Metenova. Via Benzinga Merck Germany Reports 5% Decline In Q2 Sales, Expects More Decline In 2023 August 03, 2023 Merck KGa Germany (OTC: MKGAF) (OTC: MKKGY) reported Via Benzinga Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List July 26, 2023 The World Health Organization (WHO) published the new editions of the Model Lists of Essential Medicines (EML) and Essen Via Benzinga Germany's Merck To Launch Semiconductor Base In China May 31, 2022 Via Benzinga Abcam Downgrade: Analyst Trims Expectations Amid Activist Investor Engagement and Potential Bid Anticipation June 20, 2023 RBC Capital Markets has downgraded Abcam PLC (NASDAQ: ABCM) from Outperform to Sector Perform with a price target of $22, Via Benzinga Analyst Says Nektar Therapeutics' Rezpeg Prioritization Likely to Spark Investor Questions April 18, 2023 Via Benzinga FDA Issues Partial Clinical Hold On Merck Germany's Multiple Sclerosis Study April 12, 2023 Via Benzinga Merck Germany Regains Exclusive Global Rights To Cancer Drug From Pfizer March 27, 2023 Via Benzinga Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval March 23, 2023 Via Benzinga With Upcoming Ovarian Cancer Data, Analyst Sees 100% Upside For Mersana Therapeutics January 20, 2023 Via Benzinga PDS Biotech, Merck Germany Enter Licensing Pact For Investigational Cancer Treatment January 03, 2023 Via Benzinga Mersana Inks Cancer Therapy Development Deal With Merck Germany December 23, 2022 Via Benzinga SpaceX Starlink's New In-Flight Connectivity Service, Amazon's NY Workers Reject Union, Celsius Network Faces Several Federal Investigations: Top Stories Wednesday, Oct. 19 October 19, 2022 Reuters US Lawmakers Plan Hearing On Kroger, Albertsons' $25B Merger Via Benzinga Germany's Merck Slapped With Formal French Investigation Related To Its Thyroid Drug October 19, 2022 The French court is reportedly investigating Germany-based Merck KGaA (OTC: MKKGY), saying the company provided misleading information regarding its thyroid drug product Levothyrox. Via Benzinga PDS Biotech Highlights Expanded Data From PDS0101 Triple Combination Trial In HPV-Positive Cancers October 11, 2022 Via Benzinga TSM Looks To Hire Over 8,000 People In 2022 January 24, 2022 Taiwan’s top two chipmakers plan to hire over 10,000 engineers in 2022 to bolster their aggressive expansion plans and maintain their technological edge, Financial... Via Benzinga Despite Palantir’s Impressive Deals, Its Losses and Valuation Make It Unappetizing January 21, 2022 Amid continued questions about the profitability and the competitive advantages of Palantir in a crowded field, PLTR stock remains a sell. Via InvestorPlace The Daily Biotech Pulse: Pfizer Strikes $5.29B COVID Pill Supply Deal With US, Roche's Spark Therapeutics Reports Positive Gene Therapy Readout, EDAP Earnings November 18, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Roche's Spark Subsidiary Reports Positive Phase 1/2 Data For Hemophilia... Via Benzinga GlaxoSmithKline, Merck KGaA End $4B Cancer Drug Pact September 30, 2021 Merck KGaA (OTC: MKGAF) and GlaxoSmithKline Plc (NASDAQ: GSK) have ended their $4 billion collaboration on cancer treatment, bintrafusp alfa. Merck said... Via Benzinga Nektar, Merck Germany, Pfizer Join Forces For Mid-Stage Bladder Cancer Study September 21, 2021 Nektar Therapeutics Inc (NASDAQ: NKTR) has entered into a new oncology clinical collaboration with Merck KGaA (OTC: MKGAF) and Pfizer Inc (NYSE... Via Benzinga Merck KGaA Pulls Plug On GSK-Partnered Cancer Drug Trial August 24, 2021 Merck KGaA's (OTC: MKGAF) announced that a Phase 2 trial of bintrafusp alfa had been discontinued, as an independent data monitoring committee has determined the... Via Benzinga Sutro Biopharma Receives Undisclosed Milestone Payment Under Bispecific ADC Collaboration with Merck June 01, 2021 Sutro Biopharma Inc (NASDAQ: STRO) has received a milestone payment under its collaboration and license agreement with the healthcare division of Merck KGaA... Via Benzinga Immutep, Merck Germany Team Up for Eftilagimod/Bintrafusp Combo Trial In Solid Tumors June 01, 2021 Immutep Limited (NASDAQ: IMMP) has announced a new collaboration and supply agreement with Germany-based Merck KGaA (OTC: MKGAF) for a Phase 1/2a INSIGHT... Via Benzinga Gene Therapy Player Vera Therapeutics Prices IPO Well Below Range At $11/Share May 14, 2021 Vera Therapeutics Inc has priced its 4.35 million share IPO at $11 per share, well below its targeted range of $14 to $16, raising $47.58 million in gross proceeds. The... Via Benzinga Topics Initial Public Offering Exposures Securities Market MERCK KGAA (MKKGY) Q1 2021 Earnings Call Transcript May 13, 2021 MKKGY earnings call for the period ending March 31, 2021. Via The Motley Fool Topics Earnings Exposures Financial UK's NICE Provisionally Rejects Coverage Of Pfizer-Merck KGaA's Bavencio As First-Line Therapy For Bladder Cancer May 10, 2021 England’s drug-cost watchdog has shown a cold-shoulder to Pfizer Inc (NYSE: PFE) and Merck KGaA’s (OTCMKTS: MKGAF) Bavencio (avelumab) as... Via Benzinga The Daily Biotech Pulse: Negative Regulatory Tidings For Provention Bio, Celcuity Soars On In-licensing Deal, 2 IPOs April 09, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 8) Aclaris Therapeutics, Inc... Via Benzinga Novartis Taps Artios In Discovery Pact To Enhance Radioligand Portfolio April 07, 2021 Novartis AG (NYSE: NVS) has struck a deal with UK-based Artios Pharma to access DNA damage response (DDR) targets that can potentially enhance its radioligand... Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.